With a reactive hepatitis B surface antigen (HBsAg), which laboratory tests should be ordered next to evaluate the infection stage and liver function?

Initial Workup for Reactive HBsAg

Order IgM anti-HBc, HBeAg/anti-HBe, quantitative HBV DNA, complete hepatic function panel (AST/ALT, alkaline phosphatase, bilirubin, albumin, PT/INR), CBC, and screening for coinfections (anti-HCV, anti-HDV, anti-HIV). 1

Distinguish Acute vs. Chronic Infection

• IgM anti-HBc is the critical first test to differentiate acute hepatitis B from chronic infection or acute exacerbation of chronic disease 1

  • Positive IgM anti-HBc indicates acute or recent infection (detectable for approximately 6 months) 1
  • Negative IgM anti-HBc with positive total anti-HBc suggests chronic infection (HBsAg positive >6 months) 1

• Total anti-HBc should be ordered alongside IgM anti-HBc to complete the serologic picture, as it appears at symptom onset and persists for life 1

Assess Viral Replication and Disease Activity

• Quantitative HBV DNA is essential for determining viral load and guiding treatment decisions 1

  • HBV DNA ≥20,000 IU/mL in HBeAg-positive patients indicates active chronic hepatitis B requiring treatment consideration 1, 2
  • HBV DNA ≥2,000 IU/mL in HBeAg-negative patients suggests active disease rather than inactive carrier state 1, 2

• HBeAg and anti-HBe testing determines replication phase 1

  • HBeAg-positive indicates high viral replication and increased infectivity 1
  • Anti-HBe-positive with low HBV DNA (<2,000 IU/mL) and normal ALT suggests inactive carrier state 1
  • Caveat: HBeAg-negative with high HBV DNA may indicate precore mutant virus, which still requires treatment 1

Evaluate Liver Function and Injury

• Complete hepatic panel including AST/ALT, alkaline phosphatase, GGT, bilirubin, albumin, and PT/INR to assess degree of liver injury and synthetic function 1, 3

• CBC to evaluate for thrombocytopenia or leukopenia, which may suggest portal hypertension from advanced fibrosis or cirrhosis 1

Mandatory Coinfection Screening

• Anti-HCV antibody testing is required as hepatitis C coinfection significantly worsens prognosis and alters management 1, 2

• Anti-HDV antibody must be checked since hepatitis D only infects in the presence of HBV and dramatically accelerates liver disease progression 1, 2

• HIV antibody/antigen testing is essential as coinfection accelerates liver disease and fundamentally changes treatment approach 2

• Anti-HAV IgG should be checked in patients <50 years to determine need for hepatitis A vaccination, as superinfection can cause fulminant hepatitis in chronic HBV carriers 1

Hepatocellular Carcinoma Surveillance

• Abdominal ultrasound and serum alpha-fetoprotein (AFP) should be ordered as baseline HCC screening, particularly if chronic infection is confirmed 1
  • This establishes baseline for biannual surveillance required in chronic HBV patients 2

Common Pitfalls to Avoid

• Do not rely solely on ALT levels to determine disease activity—patients can have significant fibrosis with normal or minimally elevated transaminases, particularly in the immune-tolerant or inactive carrier phases 1

• The "window period" can cause diagnostic confusion: when HBsAg has cleared but anti-HBs is not yet detectable, only IgM anti-HBc will be positive, which could be misinterpreted as isolated anti-HBc 1

• Isolated anti-HBc positivity (negative HBsAg, negative anti-HBs, positive total anti-HBc) requires HBV DNA testing to rule out occult hepatitis B, especially before immunosuppression 2, 4

• Repeat HBsAg testing in 6 months is mandatory if this is the first positive result, as persistence beyond 6 months defines chronic infection and triggers different management algorithms 1